Angina Pectoris Drugs Market 2024 - Size, Share, Trends Analysis Report, and Forecasts until 2033

The angina pectoris drugs market size has grown strongly in recent years. It will grow from $11.82 billion in 2023 to $12.47 billion in 2024 at a compound annual growth rate (CAGR) of 5.5%. The growth in the historic period can be attributed to high prevalence of cardiovascular diseases, aging population demographics, lifestyle factors, increase in hypertension rates, diabetes prevalence ..

The angina pectoris drugs market size is expected to see strong growth in the next few years. It will grow to $15.48 billion in 2028 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to rising global obesity rates, advancements in precision medicine, focus on preventive cardiology, patient education initiatives, research on novel therapeutic targets .. Major trends in the forecast period include telemedicine for remote monitoring, real-world evidence and outcome studies, patient-centric medication education, strategic alliances for market access, regulatory advances and expedited approvals..

Market Overview -
Angina pectoris drugs are medications used to treat angina pectoris, a medical illness that causes chest pain or discomfort when a portion of the heart does not receive enough blood and oxygen. Angina pectoris drugs treat chest pain or discomfort due to coronary heart disease.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=10797&type=smp

Surging Prevalence Of Chronic Angina Pectoris Propels Growth In The Angina Pectoris Drug Market
The increasing prevalence of chronic angina pectoris is expected to propel the growth of the angina pectoris drug market going forward. Chronic angina pectoris is chest pain or discomfort caused by reduced blood flow to the heart muscle. Angina pectoris drugs are vital in treating chronic angina. They can provide several benefits to those suffering from this illness, including coronary heart disease, cardiovascular disease, high blood pressure, and being overweight or obese. For instance, in May 2023, according to the Centers for Disease Control and Prevention Highlights, a US-based intergovernmental organization, coronary heart disease killed round 375,476 people in 2021 where, roughly one in every twenty people aged 20 and over (5%). Further, in 2021, almost 2 out of every 10 deaths from coronary artery disease are expected to occur in people under 65. Furthermore, in December 2022, according to the National Library of Medicine, a national center for biological information, Angina affects more than 10 million people in the United States, with more than 500,000 new diagnoses each year. Therefore, the increasing prevalence of chronic angina pectoris is driving the growth of the angina pectoris drug market.

Competitive Landscape -
Major companies operating in the angina pectoris drugs market report are Astellas Pharma Inc., Bayer AG, Novartis AG, AstraZeneca PLC, Amgen Inc., Gilead Sciences Inc., Bausch Health Companies Inc., Merck & Co Inc., Eli Lilly and Company, Otsuka Pharmaceutical Co Ltd., Pfizer Inc., Teva Pharmaceutical Industries Ltd., Abbott Laboratories, AbbVie Inc., Sun Pharmaceutical Industries Limited, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Sanofi SA, Sun BioPharma Inc., Atox Bio Inc., CalciMedica Inc., D-Pharm Ltd., Dynavax Technologies Corporation, Fresenius SE & Co KGaA, Olympus Corporation, SCM Lifescience Co. Ltd., Allergan plc, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Vertex Pharmaceuticals Incorporated, Johnson & Johnson,

Hikma Pharmaceuticals Unveils Labetalol Hydrochloride Injection, Usp, Marking A Milestone In Angina Pectoris Drug Market
Product innovation is a key trend gaining popularity in angina pectoris drugs market. Major companies operating in the angina pectoris drug market are adopting new technologies to sustain their position in the market. For instance, in March 2023, Hikma Pharmaceuticals plc, a UK-based pharmaceutical company, launched Labetalol Hydrochloride Injection, USP, in a prefilled syringe. The Food and Drug Administration of the United States has authorized this product. In hospitals, 10 mg/2 mL PFS is used to treat severe hypertension and lower blood pressure.

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/angina-pectoris-drugs-global-market-report

Key Segments -
The angina pectoris drugs market covered in this report is segmented -
1) By Drugs: Nitrates, Antiplatelet Agents, Beta-adrenergic Blocking Agents, Calcium Channel Blockers, Anti-ischemic Agents, Statins, Antihypertensive Agents, Other Drugs
2) By Indication: Stable Angina, Unstable Angina, Prinzmetal's Angina
3) By Route of Administration: Oral, Parenteral, Transdermal, Other Route Of Administrations
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database
The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.